Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Screening for PPAR Non-Agonist Ligands Followed by Characterization of a Hit, AM-879, with Additional No-Adipogenic and cdk5-Mediated Phosphorylation Inhibition Properties

Full text
Author(s):
Ribeiro Filho, Helder Veras [1, 2] ; Videira, Natalia Bernardi [1, 2] ; Bridi, Aline Villanova [2] ; Tittanegro, Thais Helena [1, 2] ; Helena Batista, Fernanda Aparecida [1] ; de Carvalho Pereira, Jose Geraldo [1] ; Lopes de Oliveira, Paulo Sergio [1] ; Bajgelman, Marcio Chaim [1] ; Le Maire, Albane [1, 3] ; Migliorini Figueira, Ana Carolina [1, 2]
Total Authors: 10
Affiliation:
[1] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, Campinas, SP - Brazil
[2] Univ Estadual Campinas, UNICAMP, Inst Biol, Post Grad Program Biosci & Technol Bioact Prod, Campinas, SP - Brazil
[3] Univ Montpellier, CNRS, Ctr Biochim Struct, Montpellier - France
Total Affiliations: 3
Document type: Journal article
Source: FRONTIERS IN ENDOCRINOLOGY; v. 9, FEB 1 2018.
Web of Science Citations: 2
Abstract

Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of a nuclear receptor superfamily and acts as a ligand-dependent transcription factor, playing key roles in maintenance of adipose tissue and in regulation of glucose and lipid homeostasis. This receptor is the target of thiazolidinediones, a class of antidiabetic drugs, which improve insulin sensitization and regulate glycemia in type 2 diabetes. Despite the beneficial effects of drugs, such as rosiglitazone and pioglitazone, their use is associated with several side effects, including weight gain, heart failure, and liver disease, since these drugs induce full activation of the receptor. By contrast, a promising activation-independent mechanism that involves the inhibition of cyclin-dependent kinase 5 (CDK5)-mediated PPAR gamma phosphorylation has been related to the insulin-sensitizing effects induced by these drugs. Thus, we aimed to identify novel PPAR gamma ligands that do not possess agonist properties by conducting a mini-trial with 80 compounds using the sequential steps of thermal shift assay, 8-anilino-1-naphthalenesulfonic acid fluorescence quenching, and a cell-based transactivation assay. We identified two non-agonist PPAR gamma ligands, AM-879 and P11, and one partial-agonist, R32. Using fluorescence anisotropy, we show that AM-879 does not dissociate the NCOR corepressor in vitro, and it has only a small effect on TRAP coactivator recruitment. In cells, AM-879 could not induce adipocyte differentiation or positively regulate the expression of genes associated with adipogenesis. In addition, AM-879 inhibited CDK5-mediated phosphorylation of PPAR gamma in vitro. Taken together, these findings supported an interaction between AM-879 and PPAR gamma; this interaction was identified by the analysis of the crystal structure of the PPAR gamma: AM-879 complex and evidenced by AM-879's mechanism of action as a putative PPAR gamma non-agonist with antidiabetic properties. Moreover, we present an optimized assay pipeline capable of detecting ligands that physically bind to PPAR gamma but do not cause its activation as a new strategy to identify ligands for this nuclear receptor. (AU)

FAPESP's process: 16/22246-0 - PPAR gamma repression mechanism as a target to combat diabetes and obesity
Grantee:Ana Carolina Migliorini Figueira
Support type: Regular Research Grants
FAPESP's process: 13/26507-4 - Complex between thyroid hormone receptor and coactivator: formation and characterization.
Grantee:Tábata Renée Doratioto
Support type: Scholarships in Brazil - Master